Psoriatic arthritis (PsA) diagnosis and management have been directed by three main sets of guidelines: the American College of Rheumatology (ACR) guidelines, the European Alliance of Associations for Rheumatology (EULAR) guidelines, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines; GRAPPA represents the most recent data, updated in 2022. New guidelines present a “domain-based approach” to therapy, in which PsA as a disease is subdivided into six domains (peripheral arthritis, axial disease, enthesitis, dactylitis, skin psoriasis [PsO], and nail PsO), and disease activity is individually assessed within each. Other guidelines, namely the 2018 ACR/National Psoriasis Foundation (NPF) guidelines, favor a treat-to-target (T2T) therapy approach that centers remission or low disease activity as a goal with specific disease management targets. Many clinicians delivering PsA care are unfamiliar with these varied guidelines, however, particularly nurse practitioners (NPs) and physician associates (PAs). It is imperative that clinicians collaborating with a multidisciplinary care team are appraised on these guideline-based management strategies to implement them competently in patients with PsA.
In the second activity of this CME Outfitters BriefCase series, expert faculty use case-based learning to demonstrate for learners how best to utilize guideline-based management strategies for patients with PsA.
